Skip to main content

High-Dose VX-548 Reduces Acute Pain Over 48 Hours

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

FRIDAY, Aug. 4, 2023 -- High-dose VX-548, an oral, highly selective inhibitor of the Nav1.8 voltage-gated sodium channel, reduces acute pain over 48 hours after abdominoplasty and bunionectomy, according to a study published in the Aug. 3 issue of the New England Journal of Medicine.

Jim Jones, M.D., Pharm.D., from Vertex Pharmaceuticals in Boston, and colleagues conducted two phase 2 trials involving participants with acute pain after abdominoplasty or bunionectomy. In the abdominoplasty trial, 303 patients were randomly assigned to receive a 100-mg oral loading dose of VX-548, followed by a 50-mg maintenance dose every 12 hours (high-dose group); a 60-mg loading dose of VX-548, followed by a 30-mg maintenance dose every 12 hours (middle-dose group); hydrocodone bitartrate-acetaminophen (5 mg of hydrocodone bitartrate and 325 mg of acetaminophen every six hours); or oral placebo every six hours in a 1:1:1:1 ratio. In the bunionectomy trial, 274 participants were randomly assigned to receive oral high-dose VX-548; middle-dose VX-548; low-dose VX-548 (a 20-mg loading dose, followed by a 10-mg maintenance dose every 12 hours); oral hydrocodone bitartrate-acetaminophen; or oral placebo every six hours in a 2:2:1:2:2 ratio.

The researchers found that in the time-weighted sum of the pain-intensity difference during the 48-hour period, the least-squares mean difference between the high-dose VX-548 and placebo groups was 37.8 and 36.8 after abdominoplasty and bunionectomy, respectively. In both trials, results were similar for those receiving lower doses of VX-548 and placebo. Common adverse events with VX-548 were headache and constipation.

"In two phase 2 clinical trials of postoperative pain, as compared with placebo, the highest dose, but not lower doses, of VX-548 reduced pain over a 48-hour period," the authors write.

Several authors disclosed ties to pharmaceutical companies, including Vertex Pharmaceuticals, the developer of VX-548.

Abstract/Full Text (subscription or payment may be required)

Editorial 1 (subscription or payment may be required)

Editorial 2 (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted August 2023

Read this next

Ulcerative Hunner Lesions Can Help Characterize Bladder Pain, Infection

TUESDAY, July 2, 2024 -- Distinct phenotypic and urine biological characteristics are seen for patients with interstitial cystitis/bladder pain syndrome (IC/BPS) with a history of...

Walking, Education Intervention Prevents Recurrence of Low Back Pain

FRIDAY, June 28, 2024 -- An individualized, progressive walking and education intervention is beneficial for prevention of recurrence of low back pain, according to a study...

Positive Family Relationships May Protect Against Pain in Older Adults

FRIDAY, June 14, 2024 -- Family support may protect against pain incidence and persistence among aging African Americans, according to a study published online May 20 in...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.